Given the growing incidence of non-communicable diseases (NCDs), such as cancer and diabetes, Apollo Hospital Enterprises Co., Ltd. will invest ₹Over the course of five years, Rs 600 billion has added 3,500 beds in key urban centres, focusing on high-load specialties such as oncology, cardiology, neuroscience and gastroenterology.
Speech MintSangita Reddy, co-managing director of Apollo Hospital, said the organization is actively working to expand its operations through a strategic two-phase growth program to bridge the country’s critical hospital infrastructure gap. “Apollo is committed to strengthening its center of excellence in cardiac science, oncology, neuroscience, orthopedics and gastric science,” she said. “This expansion will add 3,512 beds through a combination of asset acquisitions, greenfield projects and brownfield development.”
The first phase will be completed by FY26, involving ₹28.8 million rupees investment, 1,737 beds were introduced in cities such as Pune, Kolkata, Hyderabad and Gurgaon. The second phase will be launched in the next 3-4 years and will add 1,775 beds in Chennai, Varanasi, Mumbai and Lucknow with additional investment ₹32.2 billion. While the main focus remains on the first floor metropolis, Apollo also plans to expand the 2-story location in India.
Apollo Hospital Enterprises’ Shares Terminated 1.15% ₹Tuesday was 6,755.90 on BSE, respectively.
Apollo sign health risks
Apollo Hospital’s latest report National Health 2025 highlights a worrying trend – many people in India suffer from chronic non-communicable diseases (also known as chronic diseases such as hypertension, obesity, heart and respiratory diseases, depression, depression and anxiety, without any symptoms).
Of the 2.5 million people screened, about 27% of the people found that there are three or more risk factors in three or more – high blood sugar, elevated blood pressure, high body mass index, high HDL (high density lipoprotein or good cholesterol) and high LDL (high density lipoprotein or bad cholesterol), – high height indicators of high height indicators. This is an important discovery and highlights the silence, aggregation nature of chronic diseases in the Indian population.
These findings highlight the growing burden of NCD in India, which has become the main cause of death and disability. The World Health Organization estimates that NCD accounts for nearly 74% of global deaths each year, while in India, they account for 63% of deaths.
The report also provides amazing health data from Apollo national screenings. Of the 257,199 asymptomatic individuals, 65% showed early signs of fatty liver disease, 85% of which were attributed to non-alcoholic fatty liver disease (NAFLD). In addition, 26% of hypertension was undiagnosed, while 23% of diabetes were newly discovered.
Screened about 285,000 students (from elementary school to college) in six states and ten cities, and data showed a steady increase in childhood obesity, with 8% of primary school students classified as overweight, and increased to 28% by college years. Shockingly, 9% of high school students and 19% of college students suffer from hypnosis, while 2% of college students show early signs of diabetes through elevated blood sugar levels.
“These figures suggest the urgent need for structured, school-based preventive health programs, lifestyle education and regular screening,” Reddy said.
Apollo now plans to share these findings with government authorities to support the development and implementation of the national NCD screening program. She added that the aim is to improve the early detection, prevention and management of chronic diseases in India.
